Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.33 |
| ▸ | CDC7 | O00311 | 2/20 | 0.32 |
| ▸ | DBF4 | Q9UBU7 | 2/20 | 0.32 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | PRPS1 | P60891 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16129491 | 0.80 | PARP1 (0.46) | PARP1S1PR1MAPTCDC7DBF4 | |
| SCHEMBL22361949 | 0.79 | PARP1 (0.45) | PARP1S1PR1MAPTCDC7DBF4 | |
| SCHEMBL11565241 | 0.79 | PARP1 (0.45) | PARP1S1PR1MAPTCDC7DBF4 | |
| SCHEMBL13759405 | 0.75 | PARP1 (0.45) | PARP1S1PR1MAPTCDC7DBF4 | |
| SCHEMBL2431453 | 0.75 | PARP1 (0.42) | PARP1S1PR1MAPTMEN1KMT2A | |
| SCHEMBL13759404 | 0.75 | PARP1 (0.42) | PARP1S1PR1MAPTCDC7DBF4 | |
| SCHEMBL15093877 | 0.73 | PARP1 (0.44) | PARP1S1PR1MAPTMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL20562251 | 0.72 | PARP1 (0.43) | PARP1S1PR1MAPTMEN1KMT2A | |
| SCHEMBL11869664 | 0.72 | ALDH1A1 (0.50) | PARP1MAPTMEN1KMT2A | |
| SCHEMBL7032609 | 0.72 | PRKCI (0.41) | PARP1MAPTMEN1CSNK2A2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8026257-B2 | Substituted heterocyclic ethers and their use in CNS disorders | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-09-27 | — | — | US | disclosed |
| US-8003806-B2 | Integrin antagonists useful as anticancer agents | OSI Pharmaceuticals, LLC (US) | 2011-08-23 | — | — | US | disclosed |
| US-7557120-B2 | Aminocyclopentyl fused heterotricylicamide modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-20090018132-A1 | Substituted Heterocyclic Ethers and Their Use in CNS Disorders | BRISTOL-MYERS SQUIBB COMPANY | 2009-01-15 | — | — | US | disclosed |
| WO-2009009411-A1 | SUBSTITUTED HETEROCYCLIC ETHERS AND THEIR USE IN CNS DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-15 | — | — | WO | disclosed |
| EP-1599206-A4 | AMINOCYCLOPENTYL FUSED HETEROTRICYLICAMIDE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO INC (US) | 2008-05-21 | — | — | EP | disclosed |
| EP-1828144-A2 | INTEGRIN ANTAGONISTS USEFUL AS ANTICANCER AGENTS | OSI Pharmaceuticals, Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20070004714-A1 | Aminocyclopentyl fused heterotricylicamide modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2007-01-04 | — | — | US | disclosed |
| US-20060116383-A1 | Integrin antagonists useful as anticancer agents | ALCATEL LUCENT (FR) | 2006-06-01 | — | — | US | disclosed |
| WO-2006053342-A2 | INTEGRIN ANTAGONISTS USEFUL AS ANTICANCER AGENTS | OSI PHARMACEUTICALS, INC. (US) | 2006-05-18 | — | — | WO | disclosed |
| EP-1599206-A2 | AMINOCYCLOPENTYL FUSED HETEROTRICYLICAMIDE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Merck & Co., Inc. (US) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004076411-A2 | AMINOCYCLOPENTYL FUSED HETEROTRICYLICAMIDE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2004-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116383-A1 | Integrin antagonists useful as anticancer agents | ITGB5, ITGA5, ITGB1 | PARP1 1388/4885S1PR1 553/4885MAPT 4745/4885 |
| US-20070004714-A1 | Aminocyclopentyl fused heterotricylicamide modulators of chemokine receptor activity | CCR2, CCR1, CCR8 | PARP1 3206/4885S1PR1 421/4885MAPT 4550/4885 |
| US-20090018132-A1 | Substituted Heterocyclic Ethers and Their Use in CNS Disorders | CNR1, CNR2, PMP22 | PARP1 4212/4885S1PR1 1406/4885MAPT 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.